OssDsign is a developer and supplier of orthobiological products. The company develops and markets products that support the body's own healing ability, such as OssDsign Catalyst, which is a nanosynthetic bone graft for dual bone formation pathways through fusion mass. The company offers its products around the global market. OssDsign was founded in 2011 and is headquartered in Uppsala.
* Q1 in line with pre-announced numbers * Minor estimate revisions, H2'26 the key catalyst * Fair value range unchanged at SEK 4.0-6.2 Weak GM in Q1, opex offset Q1 sales confirmed the pre-announced number of SEK 36.9m (0% vs. ABGSCe) with an organic...
* In line with pre-announced numbers * Adj. EBIT -2% vs ABGSCe * No change in outlook, cautious near-term Q1 results OssDsign pre-announced preliminary Q1 sales and an EBIT range on 10 April. The reported figures are in line with the preliminary figures...
* Has already pre-announced sales and EBIT for Q1 * We assume a recovery in sales growth in H2'26e * Q1'26 results due 5 May Q1'26 expectations OssDsign pre-announced preliminary Q1 sales of SEK 36.9m and an expected EBIT range of SEK -12m to -14m for...
* Profit warning ahead of Q1'26 - results due 5 May * 3.6% organic decline in sales (-17% in SEK) * Mid-range EBIT for Q1'26e implies -23% on ABGSCe FY'26e Q1 sales 24% below ABGSCe OssDsign has pre-announced Q1'26 sales of USD 4m, or SEK 37m, and EBIT...
* Mixed Q4 but continued operational leverage * Estimates down on adj. EBIT for '26e-'27e (larger loss) * Fair value range down to SEK 7-14 (9-14) Lower sales but improving quality of earnings OssDsign reported a mixed Q4, with sales below expectations...
* 24% organic sales growth in Q4 (ABGSCe +27%) Adj. EBIT -2% vs ABGSCe * No change in outlook Q4 results OssDsign reported a mixed set of numbers in Q4 with lower sales but higher gross margin and good cost control. Q4 sales came in at SEK 45.1m (-5%...
* 27% y-o-y organic sales growth in Q4'25e * No change to financial targets expected Q4'25 results due 3 February Q4'25 expectations We believe OssDsign will continue to deliver solid sales growth for Catalyst in the US and pencil in 27% organic growth...
* Mark Waugh appointed new CEO* Relevant background from orthapaedic industry* Supportive for sentiment Getting ready for the next phase OssDsign has appointed Mark Waugh as its new CEO, effective 1 January 2026. Waugh joins from Medacta USA, where he...